Journal
JOURNAL OF ORAL PATHOLOGY & MEDICINE
Volume 51, Issue 8, Pages 694-701Publisher
WILEY
DOI: 10.1111/jop.13320
Keywords
biologics; drug treatment; interleukin inhibitor; refractory recurrent aphthous stomatitis; tumor necrosis factor-alpha inhibitor
Categories
Funding
- National Natural Science Foundation of China
- Sichuan Province Science and Technology Planning Project
Ask authors/readers for more resources
Refractory recurrent aphthous stomatitis (RRAS) is a disease characterized by severe ulcerative lesions of the oral mucosa that do not respond well to conventional therapy. Biologics have emerged as a promising targeted therapy for RRAS, offering a more precise and hopeful treatment approach.
Refractory recurrent aphthous stomatitis (RRAS) manifests as severe ulcerative lesions of the oral mucosa with poor healing and a poor response to conventional therapy, with or without systemic diseases. Its treatment remains a clinical challenge owing to the lack of effective therapies. Recently, biologics have emerged as promising targeted therapies for RRAS. The biologics targeting specific inflammatory pathways involved in the pathogenesis of RRAS, including tumor necrosis factor-alpha inhibitors and interleukin inhibitors, offer a more precise and promising therapeutic approach for RRAS. These targeted therapies have been shown to promote healing and decrease recurrence frequency in, and improve the quality of life of patients with RRAS. Herein, the types and mechanisms of biologics currently used to treat RRAS have been reviewed; furthermore, the dose, duration, therapeutic efficacy, and adverse effects of RRAS with or without certain associated systemic diseases, and the current problems and future directions have been discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available